Lyme Disease Diagnostics Market to Reach USD 1,785.6 Million by 2031 as Tick-Borne Illness Cases Climb

The global Lyme disease diagnostics market is expanding at a measured but consistent pace as climate change extends tick habitats and public health systems worldwide invest in earlier, more accurate detection methods. Industry data places the market's 2023 valuation at approximately USD 1,387.3 million, with growth expected to lift the figure from USD 1,418.3 million in 2024 to nearly USD 1,785.6 million by 2031 — a compound annual growth rate of 3.34% across the forecast window. While this pace is more modest than some adjacent diagnostics categories, it reflects a steady, structurally-driven demand curve tied directly to rising disease incidence.

A Disease on the Rise

Lyme disease diagnostics encompass the various technologies and testing methodologies used to detect Borrelia burgdorferi, the bacterium responsible for the illness. The two dominant diagnostic approaches are serological testing, which identifies antibodies the immune system produces in response to infection, and polymerase chain reaction (PCR) assays, which detect bacterial DNA directly. Both approaches have seen substantial refinement in recent years as manufacturers work to improve sensitivity and reduce diagnostic ambiguity.

The scale of the public health challenge is significant. The U.S. Centers for Disease Control and Prevention estimates that approximately 476,000 Americans are diagnosed and treated for Lyme disease annually, while more than 63,000 confirmed cases were reported in the United States in 2022 alone. Public health researchers have noted substantial growth in Lyme disease case counts over roughly the past decade and a half, a trend widely attributed to expanding tick habitats driven by shifting climate patterns — a dynamic that shows little sign of reversing and continues to underpin long-term demand for diagnostic solutions.

Technological Advancement Driving Accuracy

A notable innovation milestone arrived in mid-2022 when Adaptive Biotechnologies introduced T-Detect Lyme, a diagnostic test that leverages the body's unique T-cell immune response to Borrelia burgdorferi-associated antigens. By translating adaptive immune system genetics into a clinical diagnostic tool, the test offers a more precise and often faster route to early diagnosis compared to conventional serological approaches — addressing one of the field's most persistent challenges: symptom overlap with other conditions that frequently leads to misdiagnosis or delayed treatment.

Regulatory approvals continue to expand the diagnostic toolkit available to clinicians. T2 Biosystems received U.S. FDA approval in mid-2022 for its T2Lyme Panel, a technology designed to identify Lyme-causing bacteria directly from a patient blood sample, offering healthcare providers a faster and more direct diagnostic pathway. The company subsequently introduced the panel commercially in North America that same year, further expanding the region's diagnostic capabilities around metabolic biomarker identification and biosignature analysis.

Segment Performance

By diagnostic type, serological testing led the market in 2023, generating approximately USD 743.4 million in revenue. Enhanced enzyme-linked immunosorbent assays (ELISA) and Western blotting techniques — both designed to detect antibodies produced in response to Borrelia burgdorferi infection — continue to anchor this segment's dominance, particularly for diagnosing later-stage infections where antibody presence is more reliably detectable.

Sample type analysis reveals blood as the overwhelmingly preferred specimen, accounting for roughly 71.56% of market share in 2023. Blood-based testing underpins both serological assays and PCR-based diagnostics, offering consistent accuracy across different stages of infection while benefiting from ongoing advances in multiplex assay technology and laboratory automation.

Among end-users, diagnostic laboratories are expected to generate the highest revenue by 2031, reaching an estimated USD 980.5 million. These facilities function as centralized testing hubs equipped with advanced PCR and serological capabilities, supporting healthcare providers with the sensitivity and specificity needed for confident clinical decision-making. Close collaboration between laboratories and treating physicians continues to enhance both diagnostic turnaround times and result interpretation accuracy.

Regional Concentration in North America

North America dominates the global Lyme disease diagnostics market, commanding roughly 55.68% of total share in 2023 with a valuation near USD 772.4 million — and it is also projected to remain the fastest-growing region, expanding at a CAGR of approximately 3.68% through 2031 to reach an estimated USD 1,019.9 million. This regional concentration reflects both the geographic prevalence of tick-borne illness across the northeastern and upper midwestern United States and the proactive diagnostic investment made by both public health authorities and private industry players operating in the region.

Europe represents the second most significant growth market, with an anticipated CAGR of roughly 3.45% over the forecast period. The region's forest-covered and rural landscapes create favorable tick habitats, driving elevated disease incidence in several countries. European governments and healthcare institutions have responded with sustained investment in diagnostic research and public health awareness campaigns, supported by robust regulatory frameworks that facilitate adoption of advanced testing technologies.

Government and Policy Support

Public sector involvement plays an outsized role in this market's trajectory. Government agencies across multiple regions continue to allocate funding toward Lyme disease research, awareness campaigns, and public health infrastructure upgrades, all aimed at improving early detection and reducing the broader societal burden of the disease. Complementary efforts — including tick surveillance programs and community education initiatives — help raise public awareness of exposure risks while simultaneously creating a more favorable regulatory environment for diagnostic innovation.

Persistent Diagnostic Challenges

Despite these advances, the market continues to grapple with a fundamental clinical challenge: symptom variability. Lyme disease presents with a wide range of manifestations that frequently overlap with other conditions, increasing the risk of misdiagnosis and delaying appropriate treatment. This diagnostic ambiguity has direct market implications, as inconsistent early detection can undermine confidence in existing testing approaches.

Industry participants are countering this challenge through continued investment in diagnostic specificity, alongside targeted educational initiatives aimed at improving clinician awareness of Lyme disease presentation patterns. The emphasis on next-generation technologies — including T-cell response-based testing and multiplex molecular panels — reflects a broader industry push toward diagnostic tools capable of cutting through the symptom overlap that has historically complicated accurate, timely diagnosis.

The Path Forward

With key players such as LabCorp, Quest Diagnostics, Abbott, Bio-Rad Laboratories, DiaSorin, F. Hoffmann-La Roche, Meridian Bioscience, QuidelOrtho, Thermo Fisher Scientific, and QIAGEN continuing to expand their diagnostic portfolios, the Lyme disease diagnostics market appears well-positioned for steady, technology-driven growth. As climate-related expansion of tick habitats continues to elevate case counts globally, and as next-generation immune-response and molecular diagnostics mature, the sector is likely to see sustained investment aimed at closing persistent gaps in early and accurate detection.